Search

everythinglearnresearchcommunity

for

Search:↓

Androgenetic alopecia, a genetic disorder affecting up to 50% of adults, is caused by an excessive response to androgens leading to hair follicle shrinkage. Treatments include FDA-approved drugs, other therapies like low-dose oral minoxidil, and hair transplantation.

The document concludes that current treatments for androgenic alopecia are not fully effective, but new therapies like botulinum toxin and PRP show promise, and future gene therapy could be beneficial.

Hair loss can be managed with treatments like minoxidil, finasteride, and others, but there are still gaps in effectiveness and off-label usage is increasing.

Finasteride lowers DHT levels and raises testosterone in a dose-dependent way.

Finasteride reduces DHT levels and affects gene expression in fish, similar to its effects in humans.

Men with early balding often have hormone levels similar to women with polycystic ovary syndrome.

Finasteride helps hair growth by reducing DHT levels.

The normal human prostate does not significantly affect blood DHT levels.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.

Finasteride may treat baldness but less effective for those with 5α-reductase deficiency.

Females with 5 alpha-reductase-2 deficiency have less body hair, no acne, normal fertility, and delayed menarche.

Androstanediol glucuronide is a reliable marker for hirsutism in women.

Family history affects onset and severity of androgenic alopecia, but treatment success depends more on therapy duration.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

Sulforaphane may help with hair growth by breaking down a hormone that causes hair loss.

Flutamide combined with a low-dose birth control pill effectively reduces excessive hair growth in women with polycystic ovarian disease.

Hirsutism in females is caused by high male hormones or sensitive hair follicles.

Iron supplements may reverse premature graying in iron-deficient individuals; ingrown nails are common in diabetics with certain risk factors; topical finasteride may reduce scalp DHT as effectively as oral finasteride; monilethrix treatment is challenging but some medications can help.

Androgens like testosterone affect hair growth and oil production differently across body parts and individuals.

Finasteride use changes brain chemicals, causing lasting sexual issues and anxiety/depression.

Estradiol-rich plasma can increase hair density faster and more effectively in male pattern baldness treatment than regular plasma.

Women with female pattern hair loss have higher levels of certain androgens, suggesting increased androgen exposure to hair follicles.

Finasteride affects brain and blood steroids, causing lasting sexual and emotional side effects.

Using micro-needling, low-level laser therapy, and platelet-rich plasma together significantly improves hair growth in people with hair loss.

Accurate method measures finasteride levels in human plasma using gas chromatography-mass spectrometry.

High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.

Men with Type 2 Diabetes have lower DHT levels, which may affect fertility and lipid profiles.

Gene variant linked to prostate cancer, hormone levels, and hair loss.

Higher androgen levels do not cause baldness in men.